YGION Biomedical develops personalized cancer vaccines that utilize neoantigen-based immunotherapy to trigger tumor-specific immune responses by harnessing the patient's own immune system. This approach aims to improve treatment efficacy and minimize side effects, enhancing the quality of life for cancer patients.
Funding
$16.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic side effects and reduced quality of life for patients. Traditional approaches may not effectively target the unique characteristics of individual tumors, resulting in suboptimal treatment outcomes.
Solution
YGION Biomedical develops personalized cancer vaccines based on neoantigen immunotherapy to stimulate tumor-specific immune responses. By analyzing each patient's tumor, YGION identifies unique neoantigens to create tailor-made therapies. These individualized treatments harness the patient's own immune system to precisely target and eliminate cancer cells, minimizing damage to healthy tissues. YGION's "plug-and-play" approach aims to improve treatment efficacy and enhance the quality of life for cancer patients by providing bespoke therapies designed to fit their unique disease profile. The company leverages cutting-edge technology platforms and expertise in immuno-oncology to develop this new generation of personalized cancer vaccines.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options and healthcare providers specializing in oncology and immunotherapy.
Features
- Identification of patient-specific neoantigens through tumor analysis
- Development of tailor-made cancer vaccines targeting unique tumor characteristics
- Activation of the patient's own immune system to recognize and destroy cancer cells
- Minimization of side effects by precisely targeting tumor cells
- Utilization of cutting-edge technology platforms in immuno-oncology